Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Conditions
- Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
- DRUG: canakinumab
- DRUG: placebo
Sponsor
Novartis Pharmaceuticals
Collaborators